ALSA Ventures has established Vantage Biosciences, a recent enterprise specializing in investing in innovative treatments for unmet healthcare requirements. Vantage Biosciences is focused on addressing the primary cause of vision impairment related to diabetes – the neuroinflammatory damage that occurs before microangiopathy and results in the deterioration of the eye's neurovascular system.